A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 2/8/2019 |
| Start Date: | April 4, 2018 |
| End Date: | June 15, 2021 |
A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer
This is a Phase 1b, open-label, multicenter study to determine the Maximum Tolerated Dose
(MTD) or Maximum Administered Dose (MAD) of poziotinib when administered with standard dosing
of T-DM1 (3.6 mg/kg IV on Day 1 of each 21-day cycle) in women with advanced or metastatic
HER2+ breast cancer. The poziotinib dose identified in Part 1 of the study will be used in
combination with standard dose of T-DM1 in Part 2 of the study to confirm the poziotinib dose
and evaluate the preliminary efficacy of the combination therapy.
(MTD) or Maximum Administered Dose (MAD) of poziotinib when administered with standard dosing
of T-DM1 (3.6 mg/kg IV on Day 1 of each 21-day cycle) in women with advanced or metastatic
HER2+ breast cancer. The poziotinib dose identified in Part 1 of the study will be used in
combination with standard dose of T-DM1 in Part 2 of the study to confirm the poziotinib dose
and evaluate the preliminary efficacy of the combination therapy.
In Part 1, the dose of poziotinib, in combination with the standard dose of T-DM1 (3.6 mg/kg
IV) on Day 1 of each cycle will be determined using a "3+3" design with up to 3 dose levels
tested beginning with 8 mg/day.
Poziotinib dose escalation/de-escalation for the next dose cohort will proceed based on the
occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of the dose cohort. Patients in
the dose cohort, if not discontinued, will continue treatment until discontinuation.
In Part 2 of the study, approximately 10 patients will be treated at the MTD/MAD to confirm
dose for safety of the combination and to evaluate preliminary efficacy. Treatment for all
patients will continue until disease progression, unacceptable toxicity, or continuation of
study treatment is not in the best interest of the patient.
The Screening period (Day -30 to Day -1) will last up to 30 days prior to Cycle 1, Day 1.
During each 21-day cycle, eligible patients will receive poziotinib at the assigned dose,
orally, once daily. T-DM1 3.6 mg/kg IV will be administered on Day 1 of each treatment cycle.
All treated patients will be followed for response until disease progression or the start of
new treatment and then for survival (3 year study duration).
IV) on Day 1 of each cycle will be determined using a "3+3" design with up to 3 dose levels
tested beginning with 8 mg/day.
Poziotinib dose escalation/de-escalation for the next dose cohort will proceed based on the
occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of the dose cohort. Patients in
the dose cohort, if not discontinued, will continue treatment until discontinuation.
In Part 2 of the study, approximately 10 patients will be treated at the MTD/MAD to confirm
dose for safety of the combination and to evaluate preliminary efficacy. Treatment for all
patients will continue until disease progression, unacceptable toxicity, or continuation of
study treatment is not in the best interest of the patient.
The Screening period (Day -30 to Day -1) will last up to 30 days prior to Cycle 1, Day 1.
During each 21-day cycle, eligible patients will receive poziotinib at the assigned dose,
orally, once daily. T-DM1 3.6 mg/kg IV will be administered on Day 1 of each treatment cycle.
All treated patients will be followed for response until disease progression or the start of
new treatment and then for survival (3 year study duration).
Inclusion Criteria:
- Patient must be female, at least 18 years of age, but not older than 90 years, with
advanced or metastatic HER2+ breast cancer and a life expectancy of more than 6 months
- Patient must have confirmed HER2 overexpression or gene-amplified tumor via
immunohistochemistry [IHC] with IHC 3+ or IHC 2+ with confirmatory fluorescence in
situ hybridization [FISH]+ or [ISH]+
- Patients must have had at least 1 line of anti-HER2 directed therapy either in the
metastatic or early-stage disease setting
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria:
- Patient has had previous treatment with poziotinib.
- Patient has received anticancer chemotherapy, TKIs, biologics, immunotherapy,
radiotherapy, or investigational treatment within 15 days. (There is no washout for
hormonal therapy for breast cancer).
- Patient has a life expectancy less than 3 years due to other malignancies.
- Patient is pregnant or breast-feeding.
We found this trial at
1
site
Click here to add this to my saved trials
